Unknown

Dataset Information

0

3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.


ABSTRACT: Mcl-1, an antiapoptotic member of the Bcl-2 family of proteins, is a validated and attractive target for cancer therapy. Overexpression of Mcl-1 in many cancers results in disease progression and resistance to current chemotherapeutics. Utilizing high-throughput screening, compound 1 was identified as a selective Mcl-1 inhibitor and its binding to the BH3 binding groove of Mcl-1 was confirmed by several different, but complementary, biochemical and biophysical assays. Guided by structure-based drug design and supported by NMR experiments, comprehensive SAR studies were undertaken and a potent and selective inhibitor, compound 21, was designed which binds to Mcl-1 with a Ki of 180 nM. Biological characterization of 21 showed that it disrupts the interaction of endogenous Mcl-1 and biotinylated Noxa-BH3 peptide, causes cell death through a Bak/Bax-dependent mechanism, and selectively sensitizes E?-myc lymphomas overexpressing Mcl-1, but not E?-myc lymphoma cells overexpressing Bcl-2. Treatment of human leukemic cell lines with compound 21 resulted in cell death through activation of caspase-3 and induction of apoptosis.

SUBMITTER: Abulwerdi FA 

PROVIDER: S-EPMC4033665 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.

Abulwerdi Fardokht A FA   Liao Chenzhong C   Mady Ahmed S AS   Gavin Jordan J   Shen Chenxi C   Cierpicki Tomasz T   Stuckey Jeanne A JA   Showalter H D Hollis HD   Nikolovska-Coleska Zaneta Z  

Journal of medicinal chemistry 20140507 10


Mcl-1, an antiapoptotic member of the Bcl-2 family of proteins, is a validated and attractive target for cancer therapy. Overexpression of Mcl-1 in many cancers results in disease progression and resistance to current chemotherapeutics. Utilizing high-throughput screening, compound 1 was identified as a selective Mcl-1 inhibitor and its binding to the BH3 binding groove of Mcl-1 was confirmed by several different, but complementary, biochemical and biophysical assays. Guided by structure-based d  ...[more]

Similar Datasets

| S-EPMC11324053 | biostudies-literature
| S-EPMC4811700 | biostudies-literature
| S-EPMC6253880 | biostudies-literature
| S-EPMC3472523 | biostudies-literature
| S-EPMC4025772 | biostudies-other
| S-EPMC4445146 | biostudies-literature
| S-EPMC4266361 | biostudies-literature
| S-EPMC2538619 | biostudies-literature
| S-EPMC4182301 | biostudies-literature
| S-EPMC2653417 | biostudies-literature